



Preliminary Program as per 09.05.2023

07:30 – 07:50	Gathering
07:50 – 08:00	Welcome opening Jacob Ramon, Israel; Laurence Klotz, Canada
Chapter 1 08:00 – 08:40	
Chairs:	Axel Bex, UK; <u>Israeli TBA</u>
08:00 – 08:10	The 2022 WHO classification of Kidney Tumors: advances and challenges Evgeny Yakirevich, USA
08:10 – 08:20	Peri-operative systemic treatment in RCC: Lessons learnt from current trials Abu Gahnem Yasmin, UK
08:20 – 08:30	Adjuvant immune checkpoint inhibitor therapy in RCC: what went wrong? Alex Bex, UK
08:30 – 08:40	Discussion



Chapter 2 08:40 – 09:30	
Chairs:	Mark Stovsky, USA; Scott Eggener, USA; <u>Israeli TBA</u>
08:40 – 08:50	Exposure to plastics and other environmental toxins: Is there a link to Prostate Cancer Max Kates, USA
08:50 – 09:00	How "Big Data" can answer tough questions in Prostate Cancer Anders Bjartell, Sweden
09:00 – 09:10	Update of PROBASE : The German risk-adapted PC screening trial Peter Albers, Germany
09:10 – 09:20	After PSA: Imaging vs Biomarkers Mark Stovsky, USA
09:20 – 09:30	Discussion



Chapter 3 09:30 – 10:20	
Chairs:	Seth Lerner, USA ; <u>Israeli TBA</u>
09.30 – 09:40	NMIBC therapeutic landscape: the moving target Mark Schoenberg, USA
09:40 – 09:50	The role of re-biopsy and long term surveillance in Trimodality Therapy for bladder cancer Adam Feldman, USA
09:50 – 10:00	Local continuous release of Gemcitabine within the bladder with the intra-vesical drug-delivery system TAR-200 for BC Peter Hammerer, Germany
10:00 – 10:10	New game changers for BCG unresponsive NMIBC Seth Lerner, USA
10:10 – 10:20	Discussion



Chapter 4 10:20 – 11:10	
Chairs:	Nirit Rosenblum, USA; <u>Israeli TBA</u>
10:20 – 10:30	Tips and tricks in Vesico-Viganal fistula repair George Kasyan, Russia
10:30 – 10:40	Challenges in post irradiation Vesico-Vaginal fistula repair Dmitry Pushkar, Russia
10.40 – 10:50	Yoni.Fit bladder support for the treatment of women with SUI Nirit Rosenblum, USA
10: 50 – 11:00	Urologic care of transgender patients: basics of gender affirming surgery Polina Reyblat, USA
11.00 – 11:10	Discussion



Chapter 5 11:10 – 11:50	
Chairs:	<u>Markus Hohenfellner</u>, Germany, <u>Israeli TBA</u>
11:10 – 11:20	The future role of surgery in advanced RCC Gennady Bratslavsky , USA
11:20 – 11:30	Heidelberg experience with RCC cava thrombus Markus Hohenfellner , Germany
11:30 – 11:40	Personal experience with cava thrombus of RCC <u>Seva Matveev</u> , Russia
11:40 – 11:50	Discussion



Chapter 6 11:50 – 12:40	
Chairs:	Adam Kibel, USA; <u>Israeli TBA</u>
11:50 – 12:00	Prostate biopsy: Trans-rectal technique using fusion Juan Ignacio Martinez-Salamanca , Spain
12:00 – 12:10	The advantages of Transperineal over Transrectal prostate biopsies Hanan Goldberg , Canada
12:10 – 12:20	Liquid biomarkers as novel tools for screening and Active Surveillance of PC Shin Egawa , Japan
12:20 – 12:30	Should GG1 Prostate cancer be called cancer? Scott Eggener, <u>USA</u>
12:30 – 12:40	Discussion



Chapter 7 12:40 – 13:10	
Chairs:	<u>Jehonathan Pinthus, Canada; Israeli TBA</u>
12:40 – 12:50	Testosterone and prostate Cancer: a Myth versus Scientific Evidences Claude Schulman , Belgium
12:50 – 13:00	Testicular sparing surgery for Testis Cancer Mark Litwin , USA
13:00 – 13:10	Discussion
13.10 – 13:40	Lunch Break
Chapter 8 13:40 – 14:20	
Chairs:	Mark Schoenberg, USA; <u>Israeli TBA</u>
13:40 – 13:50	Open vs. robotic cystoprostatectomy: Is the die cast? Igor Tsaour , Germany
13:50 – 14:00	Preventing re-admissions after Radical Cystectomies using novel strategies Benjamin Davies , USA



14:00 – 14:10	Shifting Sands in Upper Tract Urothelial Cancer Vitaly Margulis, USA
14:10 – 14:20	Discussion
Chapter 9 14:20 – 14:50	
Chairs:	Juan Ignacio Martinez-Salamanca, Spain; <u>Israeli TBA</u>
14:20 – 14:30	Transperineal Laser ablation of BPH and Prostate Cancer: How is this like driving a Ferrari? <u>Fernando Bianco, USA</u>
14:30 – 14:40	Ablation of Low Risk Prostate Cancer <u>Michael A. Daneshvar, USA</u>
14:40 – 14:50	Discussion



Chapter 10 14:50 – 15:30	
Chairs:	Mark Litwin, USA ; Israeli TBA
14:50 – 15:00	Management of High Risk Prostate Cancer: what urologists should be aware of? Adam Kibel, USA
15:00 – 15:10	Cardiovascular health of prostate cancer patients: RADICAL-PC trial and beyond” Jehonatan Pinthus, Canada
15:10 – 15:20	Optimizing strategies for the treatment of patients with low burden oligometastatic prostate cancer: Is cure possible? Michael Zelefsky, USA
15:20 – 15:30	Discussion
Chapter 11 15:30 – 16:10	
Chairs:	Claude Schulman, Belgium; Israeli TBA
15:30 – 15:40	Jack and his Beanstalk: Platelet Rich Plasma and Magic Beans Ryan Terlecki, USA
15:40 – 15:50	The FIZE kUO®: Urine Output Finally Enters the Digital Age Kevin Slawin, USA



15:50 – 16:00	Is BPH surgery in ambulatory care a myth or a reality? Reduane Rabii , Morocco
16:00 – 16:10	Discussion
Chapter 12 16:20 – 16:50	
Chairs:	Peter Albers , Germany; Israeli TBA
16:20 – 16:30	The long term risks of adverse pathological results and metastases in men on AS for early stage PC Arnaud Villers , France
16.30 – 16:40	Active Surveillance for PC in patients awaiting kidney transplant Marc-Olivier Timsit , France
16.40 – 16:50	Discussion



Chapter 13 16:50 – 17:20	
Chairs:	Dmitry Pushkar, Russia; Israeli TBA
16.50 – 17:00	My opinion on the most significant steps during RALP Claude Abbou, France
17:00 – 17:10	Surgeon as an independent predictor of outcomes of Radical Prostatectomy Karim Touijers, USA
17:10 – 17:20	Discussion
Chapter 14 17:20 – 18:00	
Chairs:	TBA
17:20 – 17:30	Auto-transplantation with pyelovesicostomy for management of medically-intractable stone disease Mark Noble, USA
17:30 – 17:40	What we can learn from men with hypospadias Warren Snodgrass, USA
17:40 – 17:50	Discussion
17:50- 18:00	Concluding Remarks Jacob Ramon, Israel; Laurence Klotz, Canada